India-based drug manufacturer Cadila Healthcare has announced that it is planning to file a Biologics License Application (BLA) for its biosimilar pegfilgrastim with the FDA by the end of 2019. To date, no developer has been successful in gaining regulatory approval in the United States or European Union for a biosimilar of the reference pegfilgrastim.
India-based drug manufacturer Cadila Healthcare has announced that it is planning to file a Biologics License Application (BLA) for its biosimilar pegfilgrastim with the FDA by the end of 2019. To date, no developer has been successful in gaining regulatory approval in the United States or European Union for biosimilars of the reference pegfilgrastim.
Cadila’s proposed biosimilar references Amgen’s innovator product, Neulasta, which brought in about $4.5 billion in global sales last year. One of the challenges of developing a biosimilar pegfilgrastim is the presence of polyethylene glycol (PEG) molecule, which is bonded to filgrastim and slows the rate at which the drug is metabolized. Cadila’s proposed biosimilar is currently undergoing a phase 1 clinical trial where it is being tested in healthy volunteers for safety.
“We are discussing to do more [biosimilars for regulated markets],” said Sharvil Patel, managing director of Cadila Healthcare, as reported by Indian media. Meanwhile, Patel said, the company is planning to “aggressively push its biosimilars in semi-regulated emerging markets to boost revenues.” Cadila expects its biosimilar sales to have the potential to reach $500 million in the next 5 to 7 years, a large increase from the $45 million it currently produces.
Cadila is familiar with the development process of biosimilars, as it has already launched 8 such products in India. However, the FDA biosimilar regulatory pathway is among the most stringent in the world, and differs significantly from that in India.
Fellow Indian drug developer Biocon, together with partner Mylan, also filed a BLA for a biosimilar pegfilgrastim with the FDA, however, the application received a complete response letter (CRL) in October relating to “data from facility requalification activities” after recent adjustments to its manufacturing plant. Biocon said that the CRL did not raise question concerning the drug’s biosimilarity, pharmacokinetic or pharmacodynamic data, clinical data, or immunogenicity. Reportedly, the manufacturers are hopeful to re-file later this year.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.